My Page
기부
로그인DMJ 뉴스레터
- 현재 페이지 경로
-
- HOME
- 회원공간
- DMJ 뉴스레터
- [KDA] Featured Articles of Diabetes and Metabolism Journal Vol. 46(4)
-
- 2022.10.21
- 관리자
- 조회 214
 |
||||
|
||||
| Dear Researchers, | ||||
| Diabetes & Metabolism Journal (DMJ) is an international, peer-reviewed, open access, online and print journal aiming at publishing original research, reviews, and commentaries on all areas related to diabetes mellitus and metabolism. It is published bimonthly, with articles in English accepted through the process of peer review. Considering your research in related areas, we cordially invite you to submit a paper to DMJ. | ||||
| Original Article- Metabolic Risk/Epidemiology | ||||
Effect of Low-Dose Persistent Organic Pollutants on Mitochondrial Function: Human and in Vitro Evidence.  |
||||
| Se-A Kim, Hoyul Lee, Sung-Mi Park, Mi-Jin Kim, Yu-Mi Lee, Young-Ran Yoon, Hyun-Kyung Lee, Hyo-Bang Moon, In-Kyu Lee, Duk-Hee Lee | ||||
| Diabetes & Metabolism Journal 2022;46(4):592-604. | ||||
 |
||||
|
Chronic exposure to low-dose persistent organic pollutants (POPs) can induce mitochondrial dysfunction. This study evaluated the association between serum POP concentrations and oxygen consumption rate (OCR) as a marker of mitochondrial function in humans and in-vitro cells. The OCRs of platelets and peripheral blood mononuclear cells (PBMCs) were assessed in 323 adults and in-vitro effects were evaluated in several cell lines. Serum concentrations of POPs were significantly associated with basal OCR levels of platelet or PBMCs. In-vitro studies also demonstrated that chronic exposure to low-dose POPs could decrease OCR levels. Low-dose POPs can induce mitochondrial dysfunction by impairing oxidative phosphorylation.
|
||||
| Original Article- Complications | ||||
| Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease. |
||||
| Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim | ||||
| Diabetes & Metabolism Journal 2022;46(4):630-639. | ||||
 |
||||
|
Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with type 2 diabetes mellitus (T2DM) and is associated with chronic kidney disease (CKD). In the present study, we investigated the association between the presence and severity of NAFLD and incident CKD in patients with T2DM and preserved renal function. Advanced liver fibrosis in NAFLD was independently associated with an increased risk of incident chronic kidney disease (CKD). However, there was no association between the presence of NAFLD and incidence of CKD.
|
||||
| Original Article- Drug/Regimen | ||||
| Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study. |
||||
| Hwi Seung Kim, Taekwan Yoon, Chang Hee Jung, Joong-Yeol Park, Woo Je Lee | ||||
| Diabetes & Metabolism Journal 2022;46(4):658-662. | ||||
 |
||||
|
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are regarded as ideal combination in patients with type 2 diabetes mellitus (T2DM). In this retrospective, real-world study of 104 patients who maintained the combination for at least 1 year, the HbA1c and fasting plasma glucose levels were decreased after 6 months that were sustained after 1 year. Bodyweight showed a decreasing trend after 6 months and were significantly reduced after 1 year. SBP, LDL-C, and TG levels were also significantly decreased. The combination of SGLT2i and GLP-1RA is effective and tolerable in T2DM patients in real-world setting.
|
||||
  |
||||
|
||||